CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.